to observe the difference between Diosmin (900 mg) with Traneximic acid (500 mg) and Mefanamic acid (250 mg) in reducing menstural blood loss in pateints of Abnormal Uterine Bleeding

Efficacy and safety of Diosmin (900 mg) given along with Tranexamic acid (500 mg) and Mefenamic acid (250 mg) in reducing menstural blood loss in patients of Abnormal Uterine Bleeding A Prospective double blind randomized controlled trial(RCT) - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/11/021844

Enrollment

320

Registered

2019-11-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N920- Excessive and frequent menstruation with regular cycle

Interventions

Intervention1: Group 2 : In Group 2 A women of age below 30 years and in Group 2 B women of age above 30 to 45 years 500 mg traneximic acid, thrice daily, from day 1 to 5 of the menstrual cycle and Me

Eligibility

Inclusion criteria

Inclusion criteria: all womwn of reproductive age group between 18 to 45 years of age having abnormal uterine bleeding of only non structural cause and those willing to participate will be included in the study

Exclusion criteria

Exclusion criteria: 1. Patients with a history of recent IUCD or hormonal therapy, 2. Anovulatory or irregular cycles, 3. Pregnancy or any pelvic pathology, 4. Coagulation disturbances 5. Polycystic ovarian disease 6. Thyroid, liver or renal Abnormal. 7. Women not willing to participate in the study

Design outcomes

Primary

Measure	Time frame
o Mean Reduction from Baseline in Menstrual Blood Loss (MBL) [Time Frame: Baseline MBL over 3 menstrual cycles] reduction of menstrual blood loss in mL. o Lab levels of HB and PBAC (pictorial blood assessment chart) Score o Menstrual flow (days) Timepoint: 3 months (after 3 menstrual cycles)	—

Secondary

Measure	Time frame
o Patient Reported Outcome Measure of Limitations in Social or Leisure Activities, physical Associated with Heavy Menstrual Bleeding o Responder Analysis - Reduction in Large Stains Timepoint: 3 Menstrual cycles	—

Countries

India

Contacts

Public ContactShubhangi Jain

All India Institute of Medical Sciences

jbsharma2000@gmail.com01126589665

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026